Clinical Trials
37 trialsNCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07371910 2026-01-28
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
NCT06255392 2025-08-15
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05192798 2025-02-27
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
The First Affiliated Hospital of Bengbu Medical University
Phase 2 Recruiting
NCT06418594 2024-12-10
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Beijing 302 Hospital
Phase 2 Recruiting
NCT05594095 2024-10-04
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05019690 2024-09-19
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Fujian Cancer Hospital
Phase 1/2 Recruiting
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT03982485 2024-04-30
APP
RenJi Hospital
Phase 2 Active not recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05889871 2023-06-05
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Fudan University
Phase 3 Unknown
NCT05447702 2023-05-22
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
West China Hospital
Phase 2 Recruiting
NCT04335006 2023-05-06
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT04303741 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04803539 2023-02-21
Artemis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Recruiting
NCT03945604 2022-08-12
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT03075462 2022-07-01
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03254654 2022-04-20
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Fudan University
Phase 2 Completed
NCT03243838 2022-02-02
LANCET
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT03580395 2021-07-09
Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Unknown
NCT02878057 2021-01-27
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT03394287 2020-10-23
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT04296370 2020-08-10
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02768415 2019-06-19
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03932526 2019-04-30
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03775928 2018-12-14
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT03735082 2018-11-08
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03650738 2018-08-29
This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03457467 2018-03-07
Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer
West China Hospital
Phase 2 Unknown
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT03086785 2018-01-17
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03348098 2017-11-28
Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT01176669 2015-09-09
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Fudan University
Phase 2 Completed
NCT01653561 2013-12-03
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Fudan University
Phase 2 Completed